title: Comparison of serum CA 19.9, CA 125 and CEA levels with severity of chronic obstructive pulmonary disease.
abstract: OBJECTIVE
  To investigate serum levels of CA 19.9, CA 125 and carcinoembryonic antigen (CEA) in patients with different stages of chronic obstructive pulmonary disease (COPD).
  
  
  METHODS
  Fifty-three consecutive patients (50 males, 3 females, mean age 67.6 +/- 10.1 years) with COPD were included in this study. Serum levels of CA 19.9, CA 25 and CEA were determined by the chemiluminescent immunometric method. Based on values obtained from pulmonary function tests, the patients were divided into 3 groups: moderate (21), severe (18) and very severe (14). Data were analyzed with a Kruskal-Wallis one-way analysis of variance test and Mann-Whitney U test.
  
  
  RESULTS
  The mean serum levels of CA 125 and CA 19.9 were significantly higher in patients with very severe COPD (p = 0.013 and p = 0.017, respectively) than in patients with severe and moderate COPD (p < 0.05). Patients with cor pulmonale had significantly high mean serum levels of CEA, CA 19.9 and CA 125 (p < 0.05). Patients using a long-acting beta-agonist and theophylline showed significantly higher mean serum levels of CA 125 than patients who were not (p < 0.05).
  
  
  CONCLUSIONS
  Data showed that the increased serum tumor markers in patients with COPD might be due to the severity of COPD, medication and cor pulmonale.
authors.affiliation: Department of Chest Diseases, School of Medicine, Dumlupinar University, Kütahya, Turkey. ismetbulut2002@gmail.com
authors.forename: I
authors.initials: I
authors.lastname: Bulut
authors.forename: P
authors.initials: P
authors.lastname: Arbak
authors.forename: A
authors.initials: A
authors.lastname: Coskun
authors.forename: O
authors.initials: O
authors.lastname: Balbay
authors.forename: A N
authors.initials: AN
authors.lastname: Annakkaya
authors.forename: O
authors.initials: O
authors.lastname: Yavuz
authors.forename: E
authors.initials: E
authors.lastname: Gülcan
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D018394:CA-125 Antigen / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008163:Luminescent Measurements; D008297:Male; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood* / Q000503:physiopathology; D012720:Severity of Illness Index; D013806:Theophylline / Q000627:therapeutic use
chemical_list: D000318:Adrenergic beta-Agonists; D014408:Biomarkers, Tumor; D001993:Bronchodilator Agents; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D018680:Cholinergic Antagonists; D005938:Glucocorticoids; D013806:Theophylline